Stock BMRN BIOMARIN PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Real-time Estimate Cboe BZX
Other stock markets
 10:58:31 2024-04-16 am EDT 		5-day change 1st Jan Change
91.12 USD -0.43% Intraday chart for BioMarin Pharmaceutical Inc. +2.51% -5.40%
Apr. 15 Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing MT
Apr. 01 Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing
MT
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
PR
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing
MT
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
AQ
Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia
MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:40 AM
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing
MT
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer
MT
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
PR
Biomarin Announces Board Changes, Effective May 20, 2024
CI
Transcript : BioMarin Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM
BioMarin Scheduled to Participate in March Investor Conferences
AQ
BioMarin Scheduled to Participate in March Investor Conferences
PR
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update
DJ
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies
RE
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme
DJ
BioMarin Pharma gets DOJ subpoena on certain drug testing programs
RE
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside
MT
Transcript : BioMarin Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 22, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMRN Stock
  4. News BioMarin Pharmaceutical Inc.